BioGeometry, a Beijing-based AI biotech focused on protein design, raised more than $100 million in Series A funding to advance its AI-driven pipeline. The round underscores continued investor appetite for generative platforms that can shorten target-to-candidate cycles. For pipeline builders, the deal also highlights how protein design remains a central wedge for AI drug discovery, with startups emphasizing end-to-end workflows rather than single-model capabilities. Terms beyond the headline size were not disclosed.